Strategies to circumvent the T315I gatekeeper mutation in the Bcr-Abl tyrosine kinase
{{output}}
Despite the remarkable success of imatinib against Bcr-Abl, development of secondary resistance, most often due to point mutations in the Bcr-Abl tyrosine kinase (TK) domain, is quite common. Of these, the T315I "gatekeeper" mutation is resistant to all curren... ...
